5.5.3. treatment nocturia. 5.5.3.1. antidiuretic therapy antidiuretic hormone arginine vasopressin (avp) plays key role body water homeostasis control urine production binding v2 receptors renal collecting ducts. arginine vasopressin increases water re-absorption urinary osmolality, decreasing water excretion total urine volume. arginine vasopressin also v1 receptor mediated vasoconstrictive/hypertensive effects short serum half-life, makes hormone unsuitable treating nocturia/nocturnal polyuria. desmopressin synthetic analogue avp high v2 receptor affinity relevant v1 receptor affinity. investigated treating nocturia , specific doses, titrated dosing, differing formulations, options route administration. studies short follow-up. global interpretation existing studies difficult due limitations, imprecision, heterogeneity inconsistencies studies. sr randomised quasi-randomised trials men nocturia found desmopressin may decrease number nocturnal voids -0.46 compared placebo short-term follow-up (up three months); intermediate-term follow-up (three twelve months) change -0.85 nocturnal voids substantial number participants without increase major adverse events . another sr comparative trials men nocturia primary presentation luts including nocturia nocturnal polyuria found antidiuretic therapy using dose titration effective placebo relation nocturnal voiding frequency duration undisturbed sleep . adverse events include headache, hyponatremia, insomnia, dry mouth, hypertension, abdominal pain, peripheral edema, nausea. three studies evaluating titrated-dose desmopressin men included, reported seven serious adverse events 530 patients (1.3%), one death. seventeen cases hyponatraemia (3.2%) seven hypertension (1.3%). headache reported 53 (10%) nausea fifteen (2.8%) . hyponatremia important concern, especially patients > 65 years age, potential life-threatening consequences. baseline values sodium 130 mmol/l used inclusion criteria research protocols. assessment sodium levels must undertaken baseline, initiation treatment dose titration treatment. desmopressin recommended high-risk groups . desmopressin oral disintegrating tablets (odt) studied separately sex-specific pivotal trials cs41 cs40 patients nocturia . almost 87% included patients nocturnal polyuria approximately 48% patients > 65 years. co-primary endpoints trials change number nocturia episodes per night baseline least 33% decrease mean number nocturnal voids baseline three months treatment. mean change nocturia episodes baseline greater desmopressin odt compared placebo (difference: women = -0.3 [95% ci: -0.5 -0.1]; men = -0.4 [95% ci: -0.6 -0.2]). 33% responder rate also greater desmopressin odt compared placebo (women: 78% vs. 62%; men: 67% vs. 50%). analysis three published placebo-controlled trials desmopressin odt nocturia showed clinically significant hyponatraemia frequent patients aged ≥ 65 years aged < 65 years dosage groups, including receiving minimum effective dose desmopressin (11% men aged ≥ 65 years vs. 0% men aged < 65 years receiving 50 mcg; 4% women ≥ 65 aged years vs. 2% women aged < 65 years receiving 25 mcg). severe hyponatraemia, defined ≤ 125 mmol/l serum sodium, rare, affecting 22 1,431 (2%) patients overall . cases series including men aged 60 treated 50 mcg odt, 12/80 men hyponatremia (non-severe) one week. hyponatraemia persistence noted 4/12 cases reduction 25 mcg . low-dose desmopressin odt approved europe, canada australia treatment nocturia ≥ 2 episodes gender-specific low doses 50 mcg men 25 mcg women; however, initially failed receive fda approval, fda citing uncertain benefit relative risks reason. following resubmission fda june 2018 desmopressin acetate sublingual tablet, 50 mcg men 25 mcg women, approved treatment nocturia due nocturnal polyuria adults awaken least two times per night void boxed warning hyponatremia. desmopressin acetate nasal spray new low-dose formulation desmopressin differs types desmopressin formulation due bioavailability route administration. desmopressin acetate nasal spray investigated two rcts including men women nocturia (over two episodes per night) mean age 66 years. average benefit treatment relative placebo statistically significant low, -0.3 -0.2 1.5 mcg 0.75 mcg doses desmopressin acetate, respectively. number patients reduction 50% nocturia episodes 48.5% 37.9%, respectively compared 30% placebo group . reported adverse event rate studies rather low, risk hyponatremia 1.2% 0.9% desmopressin acetate 1.5 mcg 0.75 mcg, respectively. desmopressin acetate nasal spray approved fda 2017 treatment nocturia due nocturnal polyuria, available europe. practical considerations: complete medical assessment made, exclude potentially non-urological underlying causes, e.g., sleep apnoea, prescribing desmopressin men nocturia due nocturnal polyuria. optimal dose differs patients, men < 65 years desmopressin treatment initiated low dose (0.1 mg/day) may gradually increased dosage 0.4 mg/day every week maximum efficacy reached. desmopressin taken daily sleeping. patients avoid drinking fluids least one hour eight hours dosing. low dose desmopressin may prescribed patients > 65 years. men ≥ 65 years older, low dose desmopressin used serum sodium concentration normal: patients monitored hyponatraemia. urologists cautious prescribing low-dose desmopressin patients under-represented trials (e.g., patients > 75 years) may increased risk hyponatraemia. 5.5.3.2. medications treat lutd lutd diagnosed considered causative nocturia, relevant medications storage (and voiding) luts may considered. applicable medications include; selective α1-adrenergic antagonists , antimuscarinics [577-579], 5-aris pde5is . however, effect size medications generally small, significantly different placebo used treat nocturia . data oab medications (antimuscarinics, beta-3 agonist) generally female-predominant population. studies specifically addressing impact oab medications nocturia men identified . benefits combination therapies consistently observed. 5.5.3.3. medications agents promote sleep , diuretics , non-steroidal anti-inflammatory agents (nsaids) phytotherapy reported associated response qol improvement . effect size medications nocturia generally small, significantly different placebo. larger responses reported medications, larger scale confirmatory rcts lacking. one rct compared melatonin+tamsulosin compared placebo+tamsulosin found difference ipss change . agents promote sleep appear reduce nocturnal voiding frequency may help patients return sleep. summary evidenceleno clinical trial pathophysiology-directed primary therapy undertaken.4no robust clinical trial behavioural therapy primary intervention undertaken.4antidiuretic therapy reduces nocturnal voiding frequency men baseline severity two voids per night.1bthere increased risk hyponatremia patients 65 years age older antidiuretic therapy.1bantidiuretic therapy increases duration undisturbed sleep.1balpha 1-blocker use associated improvements undisturbed sleep duration nocturnal voiding frequency, generally marginal clinical significance.2antimuscarinic medications reduce night-time urinary urgency severity, reduction overall nocturia frequency small non-significant.2antimuscarinic medications associated higher incidence dry mouth compared placebo.25α-reductase inhibitors reduce nocturia severity men baseline nocturia severity two voids per night.2a trial timed diuretic therapy may offered men nocturia due nocturnal polyuria. screening hyponatraemia undertaken baseline treatment.1b recommendationsstrength ratingtreat underlying causes nocturia, including behavioural, systemic condition(s), sleep disorders, lower urinary tract dysfunction, combination factors.weakdiscuss behavioural changes patient reduce nocturnal urine volume episodes nocturia improve sleep quality.weakoffer desmopressin decrease nocturia due nocturnal polyuria men < 65 years age.weakoffer low dose desmopressin men > 65 years age nocturia least twice per night due nocturnal polyuria.weakscreen hyponatraemia baseline, day three day seven, one month initiating therapy periodically treatment. measure serum sodium frequently patients > 65 years age patients increased risk hyponatraemia.strongdiscuss patient potential clinical benefit relative associated risks use desmopressin, especially men > 65 years age.strongoffer α1-adrenergic antagonists treating nocturia men nocturia associated luts.weakoffer antimuscarinic drugs treating nocturia men nocturia associated overactive bladder.weakoffer 5α-reductase inhibitors treating nocturia men nocturia associated luts enlarged prostate (> 40 ml).weakdo offer phosphodiesterase type 5 inhibitors treatment nocturia.weak